IART PE Ratio & Valuation, Is IART Overvalued

Historical Valuation

Integra Lifesciences Holdings Corp (IART) is now in the Undervalued zone, suggesting that its current forward PE ratio of 5.04 is considered Undervalued compared with the five-year average of 13.93. The fair price of Integra Lifesciences Holdings Corp (IART) is between 17.30 to 34.62 according to relative valuation method. Compared to the current price of 9.55 USD , Integra Lifesciences Holdings Corp By Undervalued By 44.8%.

Relative Value

Fair Zone

17.30-34.62

Current Price：9.55

44.8%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Integra Lifesciences Holdings Corp (IART) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Integra Lifesciences Holdings Corp (IART) has a current Price-to-Book (P/B) ratio of 0.90. Compared to its 3-year average P/B ratio of 1.47, the current P/B ratio is approximately -38.75% higher. Relative to its 5-year average P/B ratio of 2.19, the current P/B ratio is about -58.85% higher. Integra Lifesciences Holdings Corp (IART) has a Forward Free Cash Flow (FCF) yield of approximately -0.48%. Compared to its 3-year average FCF yield of 2.04%, the current FCF yield is approximately -123.69% lower. Relative to its 5-year average FCF yield of 3.11%, the current FCF yield is about -115.50% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for IART competitors is 2.85, providing a benchmark for relative valuation. Integra Lifesciences Holdings Corp Corp (IART.O) exhibits a P/S ratio of 0.56, which is -80.24% above the industry average. Given its robust revenue growth of -1.74%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of IART increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of IART in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is IART currently overvalued or undervalued?

Integra Lifesciences Holdings Corp (IART) is now in the Undervalued zone, suggesting that its current forward PE ratio of 5.04 is considered Undervalued compared with the five-year average of 13.93. The fair price of Integra Lifesciences Holdings Corp (IART) is between 17.30 to 34.62 according to relative valuation method. Compared to the current price of 9.55 USD, Integra Lifesciences Holdings Corp is Undervalued By 44.80%.

What is Integra Lifesciences Holdings Corp (IART) fair value?

IART's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Integra Lifesciences Holdings Corp (IART) is between 17.30 to 34.62 according to relative valuation method.

How does IART's valuation metrics compare to the industry average?

The average P/S ratio for IART's competitors is 2.85, providing a benchmark for relative valuation. Integra Lifesciences Holdings Corp Corp (IART) exhibits a P/S ratio of 0.56, which is -80.24% above the industry average. Given its robust revenue growth of -1.74%, this premium appears unsustainable.

What is the current P/B ratio for Integra Lifesciences Holdings Corp (IART) as of Mar 11 2026?

As of Mar 11 2026, Integra Lifesciences Holdings Corp (IART) has a P/B ratio of 0.90. This indicates that the market values IART at 0.90 times its book value.

What is the current FCF Yield for Integra Lifesciences Holdings Corp (IART) as of Mar 11 2026?

As of Mar 11 2026, Integra Lifesciences Holdings Corp (IART) has a FCF Yield of -0.48%. This means that for every dollar of Integra Lifesciences Holdings Corp's market capitalization, the company generates -0.48 cents in free cash flow.

What is the current Forward P/E ratio for Integra Lifesciences Holdings Corp (IART) as of Mar 11 2026?

As of Mar 11 2026, Integra Lifesciences Holdings Corp (IART) has a Forward P/E ratio of 5.04. This means the market is willing to pay $5.04 for every dollar of Integra Lifesciences Holdings Corp's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Integra Lifesciences Holdings Corp (IART) as of Mar 11 2026?

As of Mar 11 2026, Integra Lifesciences Holdings Corp (IART) has a Forward P/S ratio of 0.56. This means the market is valuing IART at $0.56 for every dollar of expected revenue over the next 12 months.

IART Valuation